Lung Cancer

1

Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort

Sanchis-Borja, Mateo, Ricordel, Charles, Chiappa, Anne Marie, Hureaux, JosÃ©, Odier, Luc, Jeannin, Gaelle, Descourt, Renaud, Gervais, Radj, Monnet, Isabelle, Auliac, Jean-Bernard, ChouaÃ¯d, Christos

Journal:

Lung Cancer

Year:

2020

Language:

english

File:

PDF, 177 KB

english, 2020

2

Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)

Eide, Inger Johanne Zwicky, Helland, Ãslaug, Ekman, Simon, Mellemgaard, Anders, Hansen, Karin Holmskov, Cicenas, Saulius, Koivunen, Jussi, GrÃ¸nberg, BjÃ¸rn Henning, Brustugun, Odd Terje

Journal:

Lung Cancer

Year:

2020

Language:

english

File:

PDF, 2.29 MB

english, 2020

3

Attenuated isolated 3â signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC

Smuk, GÃ¡bor, Pajor, GÃ¡bor, Szuhai, KÃ¡roly, Morreau, Hans, KocsmÃ¡r, IldikÃ³, KocsmÃ¡r, Ãva, Pajor, LÃ¡szlÃ³, KajtÃ¡r, BÃ©la, SÃ¡rosi, Veronika, Lotz, GÃ¡bor, TornÃ³czky, TamÃ¡s

Journal:

Lung Cancer

Year:

2020

File:

PDF, 893 KB

2020

4

Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma

Kneuertz, Peter J., Carbone, David P., DâSouza, Desmond M., Shilo, Konstantin, Abdel-Rasoul, Mahmoud, Zhao, Weiqiang, Williams, Terrance M., Jones, Daniel, Merritt, Robert E.

Journal:

Lung Cancer

Year:

2020

File:

PDF, 948 KB

2020

5

A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab

Zhou, Yuling, Jiang, Wenjuan, Zeng, Liang, Mi, Jinye, Song, Lianxi, Lizaso, Analyn, Mao, Xinru, Yang, Nong, Zhang, Yongchang

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.50 MB

2020

6

Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients

Boysen Fynboe Ebert, Eva, McCulloch, Tine, Holmskov Hansen, Karin, Linnet, Hanne, Sorensen, Boe, Meldgaard, Peter

Journal:

Lung Cancer

Year:

2020

File:

PDF, 495 KB

2020

7

Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)

Sherman, Shira, Rotem, Ofer, Shochat, Tzippy, Zer, Alona, Moore, Assaf, Dudnik, Elizabeth

Journal:

Lung Cancer

Year:

2020

File:

PDF, 503 KB

2020

8

Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas

Trejo Bittar, Humberto E., Jerome, Jacob A., Hartman, Douglas, Pantanowitz, Liron, Mehrad, Mitra, Dacic, Sanja

Journal:

Lung Cancer

Year:

2020

File:

PDF, 947 KB

2020

9

Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer

Karayama, Masato, Yoshizawa, Nobuko, Sugiyama, Masataka, Mori, Kazutaka, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Nakamura, Yutaro, Inui,

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.38 MB

2020

10

SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer

Ma, Li, Zhang, Quan, Dong, Yujie, Li, Haoyang, Wang, Jinghui

Journal:

Lung Cancer

Year:

2020

File:

PDF, 3.06 MB

2020

11

Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy

Veronesi, Giulia, Navone, NiccolÃ², Novellis, Pierluigi, Dieci, Elisa, Toschi, Luca, Velutti, Laura, Solinas, Michela, Vanni, Elena, Alloisio, Marco, Ghislandi, Simone

Journal:

Lung Cancer

Year:

2020

File:

PDF, 753 KB

2020

12

Aims and Scope/Editorial Board

Journal:

Lung Cancer

Year:

2020

File:

PDF, 78 KB

2020

13

Volume 143

Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort

Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)

Attenuated isolated 3â signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC

Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma

A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab

Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients

Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)

Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas

Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer

SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer

Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy

Aims and Scope/Editorial Board

Contents